Articoli con mandati relativi all'accesso pubblico - Jean-Mathieu BeauregardUlteriori informazioni
Non disponibili pubblicamente: 3
Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy
F Arsenault, JM Beauregard, F Pouliot
Current Opinion in Supportive and Palliative Care 12 (3), 359-365, 2018
Mandati: Fonds de recherche du Québec - Santé, Prostate Cancer Canada
Posterior cingulate cortex hypometabolism in non-amnestic variants of Alzheimer’s disease
D Bergeron, JM Beauregard, JP Soucy, L Verret, S Poulin, JA Matias-Guiu, ...
Journal of Alzheimer's Disease 77 (4), 1569-1577, 2020
Mandati: Canadian Institutes of Health Research
New developments in the imaging of metastatic prostate cancer
JM Beauregard, F Pouliot
Current Opinion in Supportive and Palliative Care 8 (3), 265-270, 2014
Mandati: Fonds de recherche du Québec - Santé, Prostate Cancer Canada
Disponibili pubblicamente: 35
Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer
O Sartor, J De Bono, KN Chi, K Fizazi, K Herrmann, K Rahbar, ST Tagawa, ...
New England Journal of Medicine 385 (12), 1091-1103, 2021
Mandati: US National Institutes of Health
Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study
MJ Morris, SP Rowe, MA Gorin, L Saperstein, F Pouliot, D Josephson, ...
Clinical Cancer Research 27 (13), 3674-3682, 2021
Mandati: US National Institutes of Health
Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial
M Del Prete, FA Buteau, F Arsenault, N Saighi, LO Bouchard, A Beaulieu, ...
European journal of nuclear medicine and molecular imaging 46, 728-742, 2019
Mandati: Canadian Institutes of Health Research, Fonds de recherche du Québec - Santé
Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study
M Del Prete, FA Buteau, JM Beauregard
European journal of nuclear medicine and molecular imaging 44 (9), 1490-1500, 2017
Mandati: Canadian Institutes of Health Research, Fonds de recherche du Québec - Santé
Accuracy of 177Lu activity quantification in SPECT imaging: a phantom study
CF Uribe, PL Esquinas, J Tanguay, M Gonzalez, E Gaudin, ...
EJNMMI physics 4, 1-20, 2017
Mandati: Natural Sciences and Engineering Research Council of Canada
FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy
JM Beauregard, AC Blouin, V Fradet, A Caron, Y Fradet, C Lemay, ...
Cancer Imaging 15, 1-10, 2015
Mandati: Fonds de recherche du Québec - Santé, Prostate Cancer Canada
Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177Lu-octreotate PRRT
M Del Prete, F Arsenault, N Saighi, W Zhao, FA Buteau, A Celler, ...
EJNMMI physics 5, 1-20, 2018
Mandati: Canadian Institutes of Health Research
Determination of gamma camera calibration factors for quantitation of therapeutic radioisotopes
W Zhao, PL Esquinas, X Hou, CF Uribe, M Gonzalez, JM Beauregard, ...
EJNMMI physics 5, 1-16, 2018
Mandati: US National Institutes of Health, Canadian Institutes of Health Research …
Potentiation of 177Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor
NK Purohit, RG Shah, S Adant, M Hoepfner, GM Shah, JM Beauregard
Oncotarget 9 (37), 24693, 2018
Mandati: Canadian Institutes of Health Research, Fonds de recherche du Québec - Santé
Health-related quality of life and pain outcomes with [177Lu] Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant …
K Fizazi, K Herrmann, BJ Krause, K Rahbar, KN Chi, MJ Morris, O Sartor, ...
The Lancet Oncology 24 (6), 597-610, 2023
Mandati: US National Institutes of Health, UK Medical Research Council
Feasibility of single-time-point dosimetry for radiopharmaceutical therapies
X Hou, J Brosch, C Uribe, A Desy, G Böning, JM Beauregard, A Celler, ...
Journal of Nuclear Medicine 62 (7), 1006-1011, 2021
Mandati: US National Institutes of Health, Canadian Institutes of Health Research …
Assessment of human biodistribution and dosimetry of 4-fluoro-11β-methoxy-16α-18F-fluoroestradiol using serial whole-body PET/CT
JM Beauregard, É Croteau, N Ahmed, JE van Lier, F Bénard
Journal of Nuclear Medicine 50 (1), 100-107, 2009
Mandati: Fonds de recherche du Québec - Santé
Increased prostate cancer glucose metabolism detected by 18f-fluorodeoxyglucose positron emission tomography/computed tomography in localised gleason 8–10 prostate cancers …
E Lavallee, M Bergeron, FA Buteau, AC Blouin, N Duchesnay, T Dujardin, ...
European urology focus 5 (6), 998-1006, 2019
Mandati: Fonds de recherche du Québec - Santé, Prostate Cancer Canada
Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours
S Adant, GM Shah, JM Beauregard
European journal of nuclear medicine and molecular imaging 47 (4), 907-921, 2020
Mandati: Canadian Cancer Society, Canadian Institutes of Health Research, Fonds de …
Accuracy of kidney dosimetry performed using simplified time activity curve modelling methods: a 177Lu-DOTATATE patient study
W Zhao, PL Esquinas, A Frezza, X Hou, JM Beauregard, A Celler
Physics in Medicine & Biology 64 (17), 175006, 2019
Mandati: Canadian Institutes of Health Research
Comprehensive SPECT/CT system characterization and calibration for 177Lu quantitative SPECT (QSPECT) with dead-time correction
A Frezza, C Desport, C Uribe, W Zhao, A Celler, P Després, ...
EJNMMI physics 7, 1-22, 2020
Mandati: Canadian Institutes of Health Research, Fonds de recherche du Québec - Santé
Role of artificial intelligence in theranostics: toward routine personalized radiopharmaceutical therapies
J Brosch-Lenz, F Yousefirizi, K Zukotynski, JM Beauregard, V Gaudet, ...
PET clinics 16 (4), 627-641, 2021
Mandati: Natural Sciences and Engineering Research Council of Canada
Le informazioni sulla pubblicazione e sul finanziamento vengono stabilite automaticamente da un software